Solution for injection in pre-filled syringe without Ustekinumab 90
Sponsors
Janssen Cilag International
Conditions
Active Psoriatic ArthritisModerate to Severe Plaque Psoriasis
Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants with Active Psoriatic Arthritis
RecruitingCTIS2023-509239-19-00
Start: 2025-04-03Target: 337Updated: 2025-10-30
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
RecruitingCTIS2024-515706-77-00
Start: 2025-05-08Target: 399Updated: 2025-08-04